An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Frazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public Fund
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Frazier Healthcare Partners announced the closing of Frazier Life Sciences Public Fund, raising nearly $830 million in an oversubscribed fund. This marks Frazier's first dedicated public life sciences fund, increasing total capital raised to over $7.1 billion. The fund targets investments in small- and mid-cap public biotech firms. Recent successful exits include Rocket Pharmaceuticals (NASDAQ: RCKT), Translate Bio (NASDAQ: TBIO), and Trillium Therapeutics (pending acquisition by Pfizer).
Positive
Raised nearly $830 million in capital commitments.
Oversubscribed fund indicates strong investor confidence.
Focus on small- and mid-cap public biotech companies can lead to growth.
Negative
None.
MENLO PARK, Calif.--(BUSINESS WIRE)--
Frazier Healthcare Partners announced today the closing of Frazier Life Sciences Public Fund, L.P., exceeding its target and closing on nearly $830 million in capital commitments in an oversubscribed fundraise.
Led by Managing Partner Albert Cha, General Partner and Portfolio Manager Jamie Brush, and Managing Partners Patrick Heron and James Topper, Frazier Life Sciences Public Fund is a long-only fund investing in small- and mid-cap public biotech companies. Frazier Life Sciences Public Fund marks Frazier’s first dedicated public life sciences fund, bringing the firm’s total committed capital raised since inception to over $7.1 billion.
“We are thrilled to announce the launch of our public life sciences fund,” stated Albert Cha, managing partner on the Frazier Life Sciences team. “We are extremely grateful to our limited partners for their support.”
Recent exits of Frazier Life Sciences public investments include ARMO BioSciences (acquired by Eli Lilly), Ignyta (acquired by Roche), Rocket Pharmaceuticals (NASDAQ: RCKT), Translate Bio (NASDAQ: TBIO, acquired by Sanofi), and Trillium Therapeutics (NASDAQ: TRIL, pending acquisition by Pfizer).
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With over $7.1 billion total capital raised, Frazier has invested in more than 200 companies, with investment types ranging from company creation and venture capital to publicly traded companies and buyouts of profitable lower-middle market companies. Headquartered in Menlo Park, Calif., the Frazier Life Sciences team invests globally in private and publicly traded companies that develop and commercialize innovative biopharmaceuticals to address important unmet medical needs. Since 2005, 61 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As.
